Institute of Infection, Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy.
RMD Open. 2021 Feb;7(1). doi: 10.1136/rmdopen-2020-001549.
The SARS-CoV-2 pandemic is a global health problem. Beside the specific pathogenic effect of SARS-CoV-2, incompletely understood deleterious and aberrant host immune responses play critical roles in severe disease. Our objective was to summarise the available information on the pathophysiology of COVID-19.
Two reviewers independently identified eligible studies according to the following PICO framework: P (population): patients with SARS-CoV-2 infection; I (intervention): any intervention/no intervention; C (comparator): any comparator; O (outcome) any clinical or serological outcome including but not limited to immune cell phenotype and function and serum cytokine concentration.
Of the 55 496 records yielded, 84 articles were eligible for inclusion according to question-specific research criteria. Proinflammatory cytokine expression, including interleukin-6 (IL-6), was increased, especially in severe COVID-19, although not as high as other states with severe systemic inflammation. The myeloid and lymphoid compartments were differentially affected by SARS-CoV-2 infection depending on disease phenotype. Failure to maintain high interferon (IFN) levels was characteristic of severe forms of COVID-19 and could be related to loss-of-function mutations in the IFN pathway and/or the presence of anti-IFN antibodies. Antibody response to SARS-CoV-2 infection showed a high variability across individuals and disease spectrum. Multiparametric algorithms showed variable diagnostic performances in predicting survival, hospitalisation, disease progression or severity, and mortality.
SARS-CoV-2 infection affects both humoral and cellular immunity depending on both disease severity and individual parameters. This systematic literature review informed the EULAR 'points to consider' on COVID-19 pathophysiology and immunomodulatory therapies.
SARS-CoV-2 大流行是一个全球性的健康问题。除了 SARS-CoV-2 的特定致病作用外,不完全理解的有害和异常宿主免疫反应在严重疾病中起着关键作用。我们的目的是总结 COVID-19 病理生理学的现有信息。
两名审查员根据以下 PICO 框架独立确定符合条件的研究:P(人群):SARS-CoV-2 感染患者;I(干预):任何干预/无干预;C(比较):任何比较;O(结果)任何临床或血清学结果,包括但不限于免疫细胞表型和功能以及血清细胞因子浓度。
在 55496 条记录中,根据特定问题的研究标准,有 84 篇文章符合纳入标准。促炎细胞因子表达,包括白细胞介素 6(IL-6),增加,特别是在严重的 COVID-19 中,尽管不如其他严重全身炎症状态高。髓样和淋巴样区室根据疾病表型受到 SARS-CoV-2 感染的不同影响。不能维持高水平的干扰素(IFN)是 COVID-19 严重形式的特征,这可能与 IFN 途径的功能丧失突变和/或存在抗 IFN 抗体有关。针对 SARS-CoV-2 感染的抗体反应在个体和疾病谱中表现出高度的可变性。多参数算法在预测存活率、住院、疾病进展或严重程度以及死亡率方面表现出不同的诊断性能。
SARS-CoV-2 感染根据疾病严重程度和个体参数影响体液和细胞免疫。这项系统综述为 EULAR 关于 COVID-19 病理生理学和免疫调节治疗的“注意事项”提供了信息。